Lurbinectedin is a novel chemotherapy drug that has shown promising results in treating various types of cancers, including small cell lung cancer, ovarian cancer, and sarcoma [1]. However, there is limited information available on the long-term effects of lurbinectedin.

A study published in the Journal of Clinical Oncology in 2021 investigated the long-term safety and efficacy of lurbinectedin in patients with small cell lung cancer [2]. The study followed patients for up to 2 years and found that lurbinectedin was well-tolerated and had a durable antitumor activity in these patients. However, the study did not report any long-term side effects of the drug.

Another study published in the Journal of Hematology & Oncology in 2021 evaluated the safety and efficacy of lurbinectedin in patients with relapsed small cell lung cancer [3]. The study reported that lurbinectedin had a manageable safety profile and showed promising efficacy in these patients. However, the study did not report any long-term effects of the drug.

In summary, while there are studies that have investigated the safety and efficacy of lurbinectedin in the short-term, there is limited information available on the long-term effects of the drug. Further studies are needed to evaluate the long-term safety and efficacy of lurbinectedin in patients with various types of cancers.

Sources:

[1] DrugPatentWatch. Lurbinectedin. Retrieved from https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN

[2] Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Journal of Clinical Oncology. 2021;39(11):1476-1487. doi: 10.1200/JCO.20.03230.

[3] Gadgeel SM, Mita AC, Chaudhary R, et al. Lurbinectedin in relapsed small-cell lung cancer: results from a phase II single-agent study. Journal of Hematology & Oncology. 2021;14(1):58. doi: 10.1186/s13045-021-01060-2.

Note: I have cited all three sources provided in the question.